LumiraDx Limited (NASDAQ:LMDX) Sees Large Increase in Short Interest
LumiraDx Limited (NASDAQ:LMDX) Sees Large Increase in Short Interest
LumiraDx Limited (NASDAQ:LMDX – Get Rating) was the recipient of a large growth in short interest in the month of November. As of November 15th, there was short interest totalling 309,800 shares, a growth of 14.7% from the October 31st total of 270,100 shares. Approximately 2.1% of the company's stock are short sold. Based on an average daily volume of 337,500 shares, the days-to-cover ratio is currently 0.9 days.
LumiraDx Limited(纳斯达克:LMDX-GET评级)是11月份空头股数大幅增长的接受者。截至11月15日,空头股数共有309,800股,较10月31日的270,100股增长14.7%。该公司约有2.1%的股票被卖空。根据日均成交量337,500股计算,目前天数与回补比率为0.9天。
Wall Street Analysts Forecast Growth
华尔街分析师预测经济增长
Several equities analysts have recently weighed in on LMDX shares. Raymond James decreased their price objective on LumiraDx from $4.00 to $3.50 and set an "outperform" rating for the company in a report on Friday, November 11th. BTIG Research decreased their price objective on LumiraDx from $7.00 to $4.00 and set a "buy" rating for the company in a report on Friday, August 19th.
几位股票分析师最近纷纷买入LMDX的股票。雷蒙德·詹姆斯在11月11日星期五的一份报告中将LumiraDx的目标价从4.00美元下调至3.50美元,并为该公司设定了“跑赢大盘”的评级。BTIG Research将LumiraDx的目标价从7.00美元下调至4.00美元,并在8月19日星期五的一份报告中为该公司设定了买入评级。
LumiraDx Price Performance
LumiraDx性价比
Shares of NASDAQ LMDX opened at $1.29 on Friday. The stock has a market capitalization of $58.36 million, a price-to-earnings ratio of -0.91 and a beta of 1.05. The business has a 50-day moving average of $1.09 and a 200-day moving average of $1.88. The company has a debt-to-equity ratio of 20.12, a current ratio of 2.91 and a quick ratio of 1.63. LumiraDx has a fifty-two week low of $0.77 and a fifty-two week high of $10.42.
上周五,纳斯达克LMDX的股价开盘报1.29美元。该股市值为5,836万美元,市盈率为-0.91,贝塔系数为1.05。该业务的50日移动均线切入位在1.09美元,200日移动均线切入位在1.88美元。该公司的债务权益比为20.12,流动比率为2.91,速动比率为1.63。LumiraDx的52周低点为0.77美元,52周高位为10.42美元。
Hedge Funds Weigh In On LumiraDx
对冲基金参与LumiraDx
LumiraDx Company Profile
LumiraDx公司简介
(Get Rating)
(获取评级)
LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care.
LumiraDx有限公司是一家医疗诊断公司。该公司专注于通过向医疗保健提供者提供关键诊断信息来转变基于社区的医疗保健。它制造和销售一种诊断平台,该平台支持各种测试,在护理点具有实验室可比的性能。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on LumiraDx (LMDX)
- Why CSL Ltd Stock Could Be Worth a Look
- MarketBeat: Week in Review 11/28 – 12/02
- Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
- Institutions Are Buying Ambarella, Should You?
- Can ZIM Defy Broad Downturn In The Container Shipping Industry?
- 免费获取StockNews.com在LumiraDx(LMDX)上的研究报告
- 为什么CSL有限公司的股票值得一看
- MarketBeat:回顾一周11/28-12/02
- Okta Inc.庆祝收益节节攀升,但他们能持续这种提振吗?
- 机构正在购买安巴雷拉,你应该吗?
- ZIM能否抵御集装箱航运业的普遍低迷?
Receive News & Ratings for LumiraDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LumiraDx and related companies with MarketBeat.com's FREE daily email newsletter.
接收LumiraDx日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对LumiraDx和相关公司的最新新闻和分析师评级的每日简要摘要。